World Biopharm Forum was formed in 2004 because after working in industry and academic environments our founder, Dr Subramanian, recognised that there was not enough interaction between research and development and its effective implementation in industries to advance the production of biologics so that they are affordable to all people.
Since its inception, Dr Subramanian has created annual conferences with the aim of increasing productivity of drugs and maintaining quality in keeping with the regulatory authorities. All conference speakers are sourced internationally and are experienced in their respective domain. Many are from the USA, Europe and UK and work in academia and industrial sectors.
Today, our conferences are attended by leading biopharmaceutical industries, academic researchers (both in universities and research institutions) and developers in industries. Historically our largest conference, in terms of attendance, was held in Gothenburg, Sweden.
Dr Subramanian remains a regular contributor to biotechnology and science through the annual publication of books. The books aim to highlight the latest updates in technologies and this includes their application in pharmaceutical and biopharmaceutical industries.
In the future, Dr Subramanian would like to see the international communities of industry, science, research & development, investors, and government with regulatory authorities come together to address the need and provision for the citizens at large. This can be achieved as we have seen in the current pandemic challenge.
Furthermore, our goal is to provide an electric forum to work together in advancing the technical need and operational strategy for implementing continuous manufacturing in pharma industries. Dr Subramanian would also like to continue bringing scientific communities together in a full residential conference of medium size as he sees it as both informative and enjoyable.
Gerard Gach, Chief Marketing Officer at YMC Process Technologies History shows that in biopharma uptake of innovation is metered, but if the invention has checked all the user need boxes its’ acceptance has an inflection point that resembles a hockey stick (hopefully pointing skyward). MCSGP*......
Mirriam Monge, Sartorius Stedim Biotech As current biological product pipelines become more diverse, product demands are varied while there is an increased pressure to keep cost of development and production down. To meet these demands, Bio-pharma innovators and CDMOs are evaluating the implementation of process......
Dave Anderson, Director of Sales and Marketing at Aber Instruments Ltd ABER continue to develop key solutions for bioprocessing and look forward to showcasing some of these developments with you over the course of World Biopharm Forum 2022 The biopharmaceutical industry relies on proven online......
Jörg Schwinde, Key Segment Manager Vaccines and monoclonal Antibodies, Eppendorf Bioprocess Center When designing strategies to reduce time and cost in biologics development and manufacturing, one must think about bioprocess intensification. The term is widely used. BioPlan Associates recently summarized it as “essentially any new......
A warm welcome to this year’s World Biopharm Forum. We look forward to welcoming you from the 22nd – 24th June 2022 at the prestigious University of Oxford. To view the full programme of events and to purchase your ticket, please visit the dedicated conference......